Polyomavirus bk neutralizing activity in human immunoglobulin preparations

Transplantation

Volumn 89, Issue 12, 2010, Pages 1462-1465

  Randhawa, Parmjeet S ^a   Schonder, Kristine ^b   Shapiro, Ron ^c   Farasati, Nousha ^a   Huang, Yuchen ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Immunoglobulins; Neutralization; Polyomavirus BK; Treatment

Indexed keywords

IMMUNOGLOBULIN; VIRUS DNA;

ANIMAL CELL; ARTICLE; BK VIRUS; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MOUSE; NONHUMAN; POLYOMAVIRUS INFECTION; PRIORITY JOURNAL; VIRUS CULTURE; VIRUS NEUTRALIZATION; VIRUS TITRATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; BK VIRUS; CATTLE; CRICETINAE; DNA, VIRAL; HEPATITIS B; HUMANS; IMMUNOGLOBULINS; IMMUNOGLOBULINS, INTRAVENOUS; KIDNEY TRANSPLANTATION; MICE; POLYOMAVIRUS INFECTIONS; SERUM ALBUMIN; TIME FACTORS;

EID: 77954087687     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181daaaf1     Document Type: Article

References (19)

1. Hirsch HH, Brennan DC, Drachenberg CB, et al. Polyomavirus-associated nephropathy in renal transplantation: Interdisciplinary analyses and recommendations. Transplantation 2005; 79: 1277.
2. Nickeleit V, Hirsch HH, Zeiler M, et al. BK-virus nephropathy in renal transplants-tubular necrosis, MHC-class II expression and rejection in a puzzling game. Nephrol Dial Transplant 2000; 15: 324.
3. Hariharan S. BK virus nephritis after renal transplantation. Kid Int 2006; 69: 655.
4. Josephson MA, Williams JW, Chandraker A, et al. Polyomavirus-asso-ciated nephropathy: Update on antiviral strategies. Transpl Infect Dis 2006; 8: 95.
5. Sener A, House AA, Jevnikar AM, et al. Intravenous immunoglobulin as a treatment for BK virus associated nephropathy: One-year follow-up of renal allograft recipients. Transplantation 2006; 81: 117.
6. Puliyanda D, Radha R, Amet N, et al. IVIG contains antibodies reactive with BK virus and may represent a therapeutic option for BKV ne-phropathy. Am J Transplant 2003; 3(suppl 5): 359.
7. Randhawa P, Viscidi R, Carter JJ, et al. Identification of species-specific and cross-reactive epitopes in human polyomavirus capsids using monoclonal antibodies. J Gen Virol 2009; 90(pt 3): 634.
8. Farasati NA, Shapiro R, Vats A, et al. Effect of leflunomide and cidofovir on replication of BK virus in an in vitro culture system. Transplantation 2005; 79: 116.
9. Randhawa PS, Vats A, Zygmunt D, et al. Quantitation of viral DNA in renal allograft tissue from patients with BK virus nephropathy. Transplantation 2002; 74: 485.
10. Lee EDH, Kemball CC, Wang J, et al. A mouse model for polyomavi-rus-associated nephropathy of kidney transplants. Am J Transplant 2006; 6: 913.
11. Wiseman AC. Polyomavirus nephropathy: A current perspective and clinical considerations. Am J Kidney Dis 2009; 54: 131.
12. Smith JM, Jordan SC. Intravenous immunoglobulin as treatment for BK virus: Nephropathy. Pediatr Transplant 2009; 13: 11.
13. Sharma AP, Moussa M, Casier S, et al. Intravenous immunoglobulin as rescue therapy for BK virus nephropathy. Pediatr Transplant 2009; 13: 123.
14. Bohl DL, Brennan DC, Ryschkewitsch C, et al. BK virus antibody titers and intensity of infections after renal transplantation. J Clin Virol 2008; 43: 184.
15. Li Y, Cleveland B, Klots I, et al. Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J Virol 2008; 82: 638.
16. Trkola A, Kuster H, Rusert P, et al. In vivo efficacy of human immunodeficiency virus neutralizing antibodies: Estimates for protective ti-ters. J Virol 2008; 82: 1591.
17. Lakhashe SK, Thakar MR, Bharucha KE, et al. Quantitation of HLA proteins incorporated by human immunodeficiency virus type 1 and assessmentofneutralizing activityof anti-HLA antibodies. J Virol2008; 82: 428.
18. Konishi E, Kitai Y, Kondo T. Utilization of complement-dependent cytotoxicity to measure low levels of antibodies: Application to non-structural protein 1 in a model of Japanese encephalitis virus. Clin Vaccine Immunol 2008; 15: 88.
19. Katpally U, Wobus CE, Dryden K, et al. Structure of antibody-neutralized murine norovirus and unexpected differences from viruslike particles. J Virol 2008; 82: 2079.